Acute myeloid leukaemia (AML) is the most common acute leukaemia affecting adults. Despite advancements in treatments, the five year survival rate remains at a dismal 24%, and the development of drug resistance is common. Therefore, new anti-cancer targets need to be identified to improve the outcomes for AML patients. One new target is a molecule involved in the growth and survival of leukaemia cells. The goal of this project is to develop a new therapy for acute myeloid leukaemia that improves survival, without increasing side effects and toxicity associated with treatment.
Improving survival from Acute myeloid leukaemia (AML) with new therapies